Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use RYALTRIS® safely and effectively. See full prescribing information for RYALTRIS. RYALTRIS (olopatadine hydrochloride and mometasone furoate monohydrate nasal spray)Initial U.S. Approval: 2022
Medication labelWhy this: Advisory · dailymed-prescription
RYALTRIS is indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older.
- generic_name
- olopatadine hydrochloride and mometasone furoate
- product_names
- olopatadine hydrochloride and mometasone furoate
- ndc
- 59467-700, 59467-700-27, 59467-700-84
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en